Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Common Equity (2020 - 2025)

Bioventus' Common Equity history spans 6 years, with the latest figure at $228.4 million for Q4 2025.

  • For Q4 2025, Common Equity rose 54.42% year-over-year to $228.4 million; the TTM value through Dec 2025 reached $228.4 million, up 54.42%, while the annual FY2025 figure was $228.4 million, 54.42% up from the prior year.
  • Common Equity reached $228.4 million in Q4 2025 per BVS's latest filing, up from $166.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $607.7 million in Q4 2021 to a low of $147.9 million in Q4 2024.
  • Average Common Equity over 5 years is $288.5 million, with a median of $223.8 million recorded in 2023.
  • Peak YoY movement for Common Equity: skyrocketed 321.51% in 2021, then plummeted 60.59% in 2023.
  • A 5-year view of Common Equity shows it stood at $607.7 million in 2021, then tumbled by 32.16% to $412.2 million in 2022, then crashed by 46.36% to $221.1 million in 2023, then plummeted by 33.09% to $147.9 million in 2024, then skyrocketed by 54.42% to $228.4 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Common Equity are $228.4 million (Q4 2025), $166.1 million (Q3 2025), and $201.3 million (Q2 2025).